Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of weekly or on-demand BIVV001 in previously treated severe hemophilia A
NL-OMON54973Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of efanesoctocog alfa in hemophilia A (2 arms), sponsored by Sanofi. Primary endpoints: Annualized bleeding rate, Adverse events and serious adverse events and 4 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON54973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54973.